On April 8, 2024, Novo Nordisk A/S, a leading global healthcare company, reported on the progress of its share repurchase program. The program, which commenced on February 6, 2024, is part of a larger plan to buy back shares worth up to DKK 20 billion over a 12-month period. As of April 5, 2024, Novo Nordisk has repurchased 1,716,500 B shares at an average price of DKK 864.38 per share, amounting to a total expenditure of DKK 1,483,709,829. The transactions were made under the Safe Harbour Rules, with the aim to repurchase B shares up to DKK 2.1 billion by April 30, 2024. Following these purchases, Novo Nordisk holds 48,257,207 B shares as treasury shares, which is about 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. Novo Nordisk is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.

On April 8, 2024, Novo Nordisk A/S, a leading global healthcare company, reported on the progress of its share repurchase program. The program, which commenced on February 6, 2024, is part of a larger plan to buy back shares worth up to DKK 20 billion over a 12-month period. As of April 5, 2024, Novo Nordisk has repurchased 1,716,500 B shares at an average price of DKK 864.38 per share, amounting to a total expenditure of DKK 1,483,709,829. The transactions were made under the Safe Harbour Rules, with the aim to repurchase B shares up to DKK 2.1 billion by April 30, 2024. Following these purchases, Novo Nordisk holds 48,257,207 B shares as treasury shares, which is about 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange. Novo Nordisk is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.